Literature DB >> 32228825

How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1.

P Conti1, C E Gallenga2, G Tetè3, Al Caraffa4, G Ronconi5, A Younes6, E Toniato7, R Ross8, S K Kritas9.   

Abstract

SARS-CoV-2, also referred to as CoV-19, is an RNA virus which can cause severe acute respiratory diseases (COVID-19), with serious infection of the lower respiratory tract followed by bronchitis, pneumonia and fibrosis. The severity of the disease depends on the efficiency of the immune system which, if it is weak, cannot stem the infection and its symptoms. The new CoV-19 spreads in the population at a rate of 0.8-3% more than normal flu and mostly affects men, since immune genes are more expressed on the X chromosome. If CoV-19 would spread with a higher incidence rate (over 10%), and affect the people who live in closed communities such as islands, it would cause many more deaths. Moreover, people from the poorest classes are most at risk because of lack of health care and should be given more assistance by the competent authorities. To avoid the aggravation of CoV-19 infection, and the collapse of the health system, individuals should remain at home in quarantine for a period of approximately one month in order to limit viral transmission. In the case of a pandemic, the severe shortage of respirators and protective clothing, due to the enormous demand and insufficient production, could lead the CoV-19 to kill a large number of individuals. At present, there is no drug capable of treating CoV-19 flu, the only therapeutic remedies are those aimed at the side effects caused by the virus, such as inflammation and pulmonary fibrosis, recognized as the first causes of death. One of the COVID-19 treatments involves inhaling a mixture of gaseous hydrogen and oxygen, obtaining better results than with oxygen alone. It was also noted that individuals vaccinated for viral and/or bacterial infectious diseases were less likely to become infected. In addition, germicidal UV radiation "breaks down" the oxygen O2 which then aggregate into O3 (ozone) molecules creating the ozone layer, capable of inhibiting viral replication and improving lung respiration. All these precautions should be taken into consideration to lower the risk of infection by CoV-19. New anti-viral therapies with new drugs should also be taken into consideration. For example, microbes are known to bind TLR, inducing IL-1, a pleiotropic cytokine, highly inflammatory, mediator of fever and fibrosis. Therefore, drugs that suppress IL-1 or IL-1R, also used for the treatment of rheumatoid arthritis are to be taken into consideration to treat COVID-19. We strongly believe that all these devices described above can lead to greater survival and. therefore, reduction in mortality in patients infected with CoV-19. Copyright 2020 Biolife Sas. www.biolifesas.org.

Entities:  

Keywords:  COVID; CoV-19; SARS-CoV-2; coronavirus; fibrosis; inflammation; lung; virus

Mesh:

Substances:

Year:  2020        PMID: 32228825     DOI: 10.23812/Editorial-Conti-2

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  50 in total

1.  Management strategies for patients with autoimmune diseases during the COVID-19 pandemic: A perspective from China.

Authors:  Yu Liu; Christopher Chang; Qianjin Lu
Journal:  Eur J Rheumatol       Date:  2020-04-10

Review 2.  Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review.

Authors:  Christodoulos Papadopoulos; Dimitrios Patoulias; Eleftherios Teperikidis; Dimitrios Mouselimis; Anastasios Tsarouchas; Maria Toumpourleka; Aristi Boulmpou; Constantinos Bakogiannis; Michael Doumas; Vassilios P Vassilikos
Journal:  SN Compr Clin Med       Date:  2020-08-04

3.  Differential mast cell numbers and characteristics in human tuberculosis pulmonary lesions.

Authors:  Karen Magdalena Garcia-Rodriguez; Estela Isabel Bini; Armando Gamboa-Domínguez; Clara Inés Espitia-Pinzón; Sara Huerta-Yepez; Silvia Bulfone-Paus; Rogelio Hernández-Pando
Journal:  Sci Rep       Date:  2021-05-21       Impact factor: 4.379

Review 4.  Can Zn Be a Critical Element in COVID-19 Treatment?

Authors:  Mohammad Tariqur Rahman; Syed Zahir Idid
Journal:  Biol Trace Elem Res       Date:  2020-05-26       Impact factor: 3.738

5.  Characteristics of inflammatory factors and lymphocyte subsets in patients with severe COVID-19.

Authors:  Ming Ni; Fang-Bing Tian; Dan-Dan Xiang; Bing Yu
Journal:  J Med Virol       Date:  2020-06-09       Impact factor: 2.327

Review 6.  Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.

Authors:  Salvatore Crisafulli; Valentina Isgrò; Laura La Corte; Fabiola Atzeni; Gianluca Trifirò
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

7.  Effect of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: Preliminary Results.

Authors:  Marcos Edgar Fernández-Cuadros; María Jesús Albaladejo-Florín; Sandra Álava-Rabasa; Isabel Usandizaga-Elio; Dolores Martinez-Quintanilla Jimenez; Daiana Peña-Lora; Inmaculada Neira-Borrajo; María Jesús López-Muñoz; Javier Rodríguez-de-Cía; Olga Susana Pérez-Moro
Journal:  SN Compr Clin Med       Date:  2020-08-03

8.  Artemisia annua: Trials are needed for COVID-19.

Authors:  Faiz Ul Haq; Muhammad Roman; Kashif Ahmad; Saeed Ur Rahman; Syed Murtaza Ali Shah; Naveed Suleman; Sami Ullah; Iftekhar Ahmad; Wajahat Ullah
Journal:  Phytother Res       Date:  2020-05-27       Impact factor: 6.388

Review 9.  Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19.

Authors:  Antony Cheudjeu
Journal:  Life Sci       Date:  2020-08-23       Impact factor: 5.037

10.  IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?

Authors:  Shubham Atal; Zeenat Fatima
Journal:  Pharmaceut Med       Date:  2020-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.